The Vasostrict brand market had U.S. sales of approximately US $ 878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Biocon has reported consolidated financial results for the period ended December 31, 2021
Ram’s appointment follows the launch of the CDI India division in October 2021.
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Subscribe To Our Newsletter & Stay Updated
